About this item:

184 Views | 179 Downloads

Author Notes:

Jonathon Cohen: jonathon.cohen@emory.edu

Thanks to Dr. David Guidot for his contributions in reviewing the manuscript.

Disclosure forms provided by the authors are available with the full text of this article online at https://doi.org/10.1080/10428194.2017.1361032.


Research Funding:

This study is supported in part by grants from the American Society of Hematology and Lymphoma Research Foundation (JBC).

Research reported in this publication was supported in part by the Biostatistics and Bioinformatics Shared Resource of Winship Cancer Institute of Emory University and NIH/NCI under award number P30CA138292.


  • Science & Technology
  • Life Sciences & Biomedicine
  • Oncology
  • Hematology
  • Mantle cell lymphoma
  • relapse
  • surveillance imaging
  • survival
  • PET/CT
  • CT
  • MCL2

Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility


Journal Title:

Leukemia & Lymphoma


Volume 59, Number 4


, Pages 888-895

Type of Work:

Article | Post-print: After Peer Review


Mantle cell lymphoma (MCL) is a heterogeneous disease with high relapse rates. Limited data guide the use of surveillance imaging following treatment. We constructed a retrospective cohort from two academic institutions of patients with MCL who completed first-line therapy and underwent follow-up for relapse, analyzing the effect of surveillance imaging on survival. Of 217 patients, 102 had documented relapse, with 38 (37%) diagnosed by surveillance imaging and 64 (63%) by other methods. Relapse diagnosis by surveillance imaging had no significant advantage in overall survival from diagnosis date (hazard ratio [HR] = 0.80, p = .39) or relapse date (HR = 0.72, p = .22). Of 801 surveillance images, PET/CT had a positive predictive value (PPV) of 24% and number needed-to-scan/treat (NNT) of 51 to detect one relapse, and CT had a PPV of 49% and NNT of 24. For MCL after first-line therapy, relapse detection by surveillance imaging was not associated with improved survival and lacks clinical benefit.

Copyright information:

© 2017 Informa UK Limited, trading as Taylor & Francis Group.

Export to EndNote